Kornimate/medical-research-clean huggingface dataset:
semantic rehabilitation for patients with primary progressive semantic aphasia

Conditions: Primary Progressive Aphasia

Summary: this project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the sced methodology.

the damage on the semantic system is at the heart of the clinical picture of semantic primary progressive aphasia (ppa), a neuro-evolutionary pathology. in other words, patients gradually lose access to concepts, general knowledge, word memory and meaning. in the absence of effective pharmacological treatment to reduce the symptoms evoked by patients and improve their quality of life, the arguments in favour of speech and language therapy are multiplying. numerous lexico-semantic multimodal indication therapies have been described in scientific studies. the most studied is semantic rehabilitation through the analysis of semantic features, which has shown its effectiveness in the context of vascular and post-traumatic aphasia. however, there are only few studies and applications in neuro-evolutionary pathologies such as semantic ppa and those studies are complicated by methodological biases. it has been shown that relearned knowledge is more likely to be retained and transferred to everyday life (generalisation) if the material used is specific to the needs of each individual. given the heterogeneity of clinical profiles in neuro-evolving pathologies and the inter-individual variability, the personalised approach should be favoured. to evaluate the effect of semantic therapy in patients with semantic ppa, this study therefore proposes to use the sced (single case experimental design) methodology. in addition to allowing an individual analysis, this methodology has the advantage of corresponding to a high level of evidence due to the acquisition of repeated measures and the randomisation of the introduction of the treatment.

Eligibility criteria:
inclusion criteria: * have a diagnosis of primary progressive semantic aphasia according to the criteria of gorno-tempini et al (2011) (appendix a) * being in the mild to moderate stage of dementia (mmse score between 10 and 28) (crum et al., 1993; derouesné et al., 1999) * common french * being affiliated to a social security scheme * being over the age of 18 years old exclusion criteria: * have significant uncorrected visual and/or hearing impairment * have a history of brain injuries, major head trauma * have untreated psychiatric disorders * have significant motor and/or comprehension problems that make it impossible to take part in the study * chronical use of drugs and/or alcohol * under guardians or curators * severe depression (beck's depression scale score \> 9) (beck \& al., 1961)

Keywords: semantic primary progressive aphasia semantic variant (svppa) speech therapy anomia metacognition single case experimental design technology naming speed of lexical access
intergenerational transmission of terror

Conditions: Anxiety; Trauma; Stress Disorders

Summary: our aim is examine avenues by which mothers can transmit their trauma to their children.

the goal of the study is to test for genetic bases and gene x environment interactions on the development of difficulties, particularly stress disorders, in young children whose mother were exposed to terror before they were born.

Eligibility criteria:
inclusion criteria: * pregnant women who were exposed to terror in the last 5 years * matched controls exclusion criteria: * does not speak hebrew or english

Keywords: trauma anxiety antenatal mothers children gene x environment interaction
anatomical variation of cerebral venous sinus in healthy individuals

Conditions: Venous Sinus Thrombosis, Cranial

Summary: the anatomical characteristics of veins and venous sinus result in great differences between cerebral venous system diseases and cerebral artery diseases in etiology, pathophysiology and clinical features.therefore, understanding the anatomy and variation of normal venous sinuses is essential to identify the intracranial venous lesions.

the classification of venous sinus and its variation based on the autopsy of patients can not fully reflect the real anatomy and variation of venous sinus in human, and the targeted research on healthy people is still unknown. the main purpose of this research is to use multimodal magnetic resonance technology to study the variation of venous sinus in chinese healthy population, to preliminarily improve the anatomical classification of venous sinus in chinese , to verify the the correlation between venous sinus variation and various non-genetic factors at the same time, as well as establishing reliable quantitative evaluation indicators.

Eligibility criteria:
inclusion criteria: 1. age 18 - 35 years old. 2. confirmed no intracranial diseases, congenital abnormalities such as intracranial hematoma, tumor, vascular malformation, hydrocephalus, etc. 3. voluntarily signed informed consent. exclusion criteria: 1. any clinical history, including hypertension, diabetes, coronary heart disease, hematologic and rheumatic immune system diseases,cervical spondylosis, anxiety, depression, insomnia, etc. 2. internal jugular venous outflow disturbance : mrv from extracranial to aortic arch demonstrates variation or stenosis of the internal jugular vein, vertebral plexus, brachiocephalic vein, and superior vena cava. 3. any history of craniocerebral trauma or surgery that affected the existence and running of veins.unhealthy habits such as smoking, heavy drinking, etc. 4. women who are pregnant or in preparation for pregnancy or lactation. 5. other conditions that the researchers considered might affect the trial and inappropriate for inclusion.

Keywords: venous sinus anatomy
low intensity pulsed ultrasound versus high intensity continuous ultrasound therapy in knee osteoarthritis

Conditions: Osteoarthritis, Knee; Osteoarthritis; Rheumatic Diseases; Musculoskeletal Diseases

Summary: to compare the effects of low intensity pulsed ultrasound with high intensity continuous ultrasound in knee osteoarthritis

knee osteoarthritis is a common disorder affecting elderly and obese. currently, there are 3 types of treatment; pharmacological, non-pharmacological and surgery. though ultrasound, a non-pharmacological treatment, is increasingly used in knee osteoarthritis, the advantages and disadvantages of low intensity pulsed ultrasound (lipus) and high intensity continuous ultrasound (hicus) are yet to be clarified. therefore, a randomized control trial will be done to compare lipus and hicus in participants with knee osteoarthritis presenting to department of physical medicine and rehabilitation, yangon general hospital, myanmar.

Eligibility criteria:
inclusion criteria: * participants with knee pain (vas 3 to 6) * kellgren and lawrence grade 2 and 3 in x' ray knee joint exclusion criteria: * rheumatoid arthritis, gouty arthritis, spondyloarthropathies, metabolic arthropathies * infection of knee joint * tumor of knee joint * history of hypersensitivity to heat * previous knee surgery in affected side * intra-articular injection within previous 3 months * participants taking treatment with other physical modalities such as low-level laser therapy and trans cutaneous electrical nerve stimulation

Keywords: low intensity pulsed ultrasound (lipus) high intensity continuous ultrasound knee pain knee stiffness randomized controlled trial myanmar osteotron
mitochondrial bioenergetics and role in cellular damage in ischemic myocardium

Conditions: Coronary Artery Disease; Diabetes Mellitus; Mitochondrial Metabolism Disorders

Summary: cardiac ischemia is a common pathological condition, known to elicit multiple pathological processes at the cellular level. one of the most affected is thought to be cellular metabolism, key for the adequate cardiac function. the aim is to study mitochondrial bioenergetic function, interaction with other cellular systems and influence of several co-morbidities in myocardium of the affected patients.

coronary artery disease, one of the most common pathologies in the developed world, causes hypoperfusion of myocardial tissue, usually evident by the presence of anginal pain. this myocardial ischemia elicits alterations in normal cardiomyocyte physiology, which gradually deteriorate cellular function, affecting the performance of the entire organ. the condition is frequently further complicated (and aggravated) by the presence of various co-morbidities, such as diabetes mellitus. the primary aim of this study is to investigate the cardiomyocyte bioenergetics and the consequences of potentially reduced mitochondrial metabolic function in ischemic heart, and evaluate the potential contribution of other conditions, primarily ones affecting metabolic homeostasis.

Eligibility criteria:
inclusion criteria: * coronary artery disease * indication for coronary artery bypass grafting surgery exclusion criteria: * emergency patients * patients with lv ejection fraction (lvef) below 30% * patients with severe renal, hepatic or pulmonary disease
phase ii study of irinotecan and cisplatin in extensive-stage small cell lung cancer

Conditions: Extensive-stage Small Cell Lung Cancer

Summary: patients with untreated extensive-stage small cell lung cancer(sclc) were randomly assigned to receive either irinotecan/cisplatin (ip) or etoposide/cisplatin(ep), the association of efficacy and toxicity of ip regimen was analyzed.

this is a randomized, multicenter study. patients are randomized to irinotecan/cisplatin (ip) or etoposide/cisplatin (ep) treatment arms. the ip regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1. the ep regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1. cycle length for the two arms was 3 weeks. the dose adjustment was allowed in at most within ±5% per investigator discretion if necessary.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) of 0 to 2 * a life expectancy of at least 3 months * measurable lesions * adequate hematologic function exclusion criteria: * infection * myocardial infarction within the preceding three months * symptomatic brain metastases or receiving radiotherapy less than 4 weeks * pregnancy or breast-feeding
partner ii: improving patient and family centered care in advanced critical illness

Conditions: Anxiety; Depression

Summary: this is a stepped wedged randomized controlled trial comparing the partner intervention with usual care in 5 intensive care units. the overarching goal of this research project to ensure patient-centered decisions about the use of intensive treatments for patients with advanced critical illness. in a prior project, the investigators developed the partner program (pairing re-engineered icu teams with nurse-driven education and outreach), a 4-facet, team-based intervention that re-engineers how surrogates are supported in icus, including: 1) changing care "defaults" to ensure clinician-family meetings within 48 hours of enrollment and frequently thereafter; 2) protocolized, nurse-administered coaching and emotional support of surrogates before and during clinician-family meetings, 3) increased use of palliative care services for patients with a poor prognosis. the investigators propose to begin deployment of the partner ii program in the spring of 2015 enrolling 690 surrogate decision makers in 5 icus using a stepped wedge design. the investigators expect to achieve the following project goals: 1. to increase the patient-centeredness of end-of-life decisions, and to increase the quality of clinician-family communication. 2. to decrease the psychological burden on family members acting as surrogates. 3. to reduce total health care costs by decreasing the duration of use of burdensome, invasive treatments at the end of life.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * surrogate decision maker for icu patient in one of 5 upmc icu's exclusion criteria: * non-english speaking * surrogate's loved one is for organ transplantation * not physically able to participate in family meeting

Keywords: decision making for incapacitated patients intensive care surrogate decision making patient centered care palliative care
nutritional status and nutrient supply in hospitalised surgical patients

Conditions: Colorectal Cancer; Esophageal Cancer; Gastric Cancer

Summary: prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing elective surgery of the upper or lower gastrointestinal tract * mental and verbal ability to understand, read and write in german language * written informed consent for study participation exclusion criteria: * age \<18 years * inadequate ability to be compliant with the study protocol or to complete documentation for the food frequency questionnaires

Keywords: nutrition surgery
efficacy and safety of intravenous efzofitimod in patients with pulmonary sarcoidosis

Conditions: Pulmonary Sarcoidosis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (iv) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. this study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (ocs), with or without immunosuppressant therapy.


Eligibility criteria:
inclusion criteria: * documented history of pulmonary sarcoidosis for at least 6 months, supported by the following evidence: documented histologically proven diagnosis of sarcoidosis by tissue biopsy and documented evidence of parenchymal lung involvement by historical radiological evidence * evidence of symptomatic pulmonary sarcoidosis, as demonstrated by the following criteria: modified medical research council (mrc) dyspnea scale grade of at least 1 and ksq-lung score ≤70 * patients must be receiving treatment with ocs of ≥ 3 months at day 1 with a starting dose between ≥ 7.5 and ≤ 25 mg/day ≥ 4 weeks prior to day 1. * body weight ≥ 40 kg and \< 160 kg exclusion criteria: * treatment with \> 1 immunosuppressant therapy * treatment with biological immunomodulators, such as tumor necrosis factor-alpha (tnf-α) inhibitors or antifibrotics or interleukin inhibitors * likelihood of significant pulmonary fibrosis as shown by any 1 or more of the following: high resolution ct fibrosis \> 20% within the last 12 months; fvc percent predicted (fvcpp) \< 50% and ksq-lung score \< 30 * in the opinion of the investigator, clinically significant pulmonary hypertension * patients with active cardiac, neuro, or renal sarcoidosis requiring organ-specific therapy in the past 2 years * patients with cutaneous or ocular sarcoidosis, which in the opinion of the investigator, are at risk for exacerbation, necessitating ocs rescue or other systemic therapy * history of addisonian symptoms that precluded previous ocs taper attempts * is an active, heavy smoker of tobacco/nicotine-containing products * history of anti-synthetase syndrome or jo-1 positive at screening * patients with active tuberculosis or those currently undergoing treatment for tuberculosis

Keywords: pulmonary sarcoidosis sarcoidosis granuloma inflammation lymphoproliferative disorders interstitial lung disease neuropilin-2 steroids oral corticosteroids immunomodulatory trna synthetase atyr1923 krp-r120 efzofitimod fibrosis
musculoskeletal complaints in an industry

Conditions: Musculoskeletal Disorder

Summary: the hypothesis of this study is that there will be a variety of factors influencing the musculoskeletal complaints among workers of different sectors. work-related musculoskeletal disorders (wmsds) account for more than 30% of occupational diseases in the world. in order to organize the strategic actions that will be developed for the prevention of msds, it is essential to analyze in advance the peculiar situations of the different sectors of a workplace. the objectives of this study were to determine the prevalence of musculoskeletal complaints among workers in a medium-sized industry by comparing its sectors and to investigate the influence of occupational and non-occupational factors in the increase of complaints.

the nordic questionnaire was used to asses musculoskeletal symptoms as well as questionnaires about lifestyle and work-related conditions in 185 workers divided into three sectors of an industry (factory - microelectronics, office and logistics)

Eligibility criteria:
inclusion criteria: * work in the industry exclusion criteria: * work less than a month in the industry

Keywords: work wmsd prevalence occupational risks industry questionnaires musculoskeletal pain lifestyle
efficacy of app and electronic device in the treatment of premature ejaculation

Conditions: Premature Ejaculation; Masturbation; Medical Device

Summary: randomized control trial to determine if we can produce increases in the ielt using a new masturbator electronic in subjects with premature ejaculation in combination with a exercise app, producing improvements in the quality and satisfaction of the sexuality of the patient.

this project of research will use one experimental groups, it will manage the affairs the therapy "sphincter control training" (sct) into app combined with the external device called myhixel i .experimental groups will receive therapy with the protocol of exercises sct. the main measure will be the "fold increase" (fi) of the ielt, which was calculated using the geometric mean of post-treatment ielts (period b) divided by the geometric mean of pre-treatment ielts (period a): fi = (geometric mean of ielt_7wk)/(geometric mean of pre_ielt) the efficiency on the ep will see (ielt) reflected in an increase in the times of latency of intravaginal ejaculation and in punctuations of subjective perception, of the therapy on the line base. the subjects that will be born in mind will be all the interested parties in informing that their answer to the campaign of national advertising that will be started. the duration of the treatment will be 8 weeks during which a series of exercises app will be practised usin the masturbation device myhixel i. the material used in the research will be innocuous and his responsible use does not produce adverse reactions of interest.

Eligibility criteria:
inclusion criteria: * aged over 18 years. * being in a heterosexual relationship for at least the last 6 months. * having a score of \>11 on the premature ejaculation diagnostic tool (pedt). * having a self-reported ielt ≤2 minutes. exclusion criteria: * a history of alcohol abuse or dependence. * having received medication or psychological treatment for pe in the last 6 months. * having diabetes. * the regular use of recreational drugs (except tobacco and caffeine).

Keywords: premature ejaculation ielt medical device
a 52 week open-label extension trial following the double-blind efficacy and safety study r076477-sch-305.

Conditions: Schizophrenia

Summary: open-label extension to the double-blind effectiveness and safety study r076477-sch-305 to evaluate long-term safety and tolerability in patients with schizophrenia.

the primary objective of the open-label extension trial was the long-term assessment of safety and tolerability of flexibly-dosed er oros paliperidone (3 to 15 mg/day) in patients with a diagnosis of schizophrenia. other measures assessed in the extension study included: change in the total positive and negative syndrome scale (panss) score; change in panss subscale (positive and negative) scores; overall functioning, as measured by the clinical global impression scale-severity (cgi-s); personal and social functioning, as measured by the personal and social performance scale (psp); and quality of life parameters, as measured by the schizophrenia quality of life scale, revision 4 (sqls-r4). paliperidone er oros® tablet formulation (3 to 15 mg/day) to be taken orally for 52 weeks

Eligibility criteria:
inclusion criteria: * study r076477-sch-707 enrolled patients who met the dsm-iv criteria of schizophrenia for at least 1 year * eligible patients were experiencing active symptoms at the time of enrollment and had a panss total score between 70 and 120 * the open-label extension study population comprised patients who had completed the 6-week double-blind phase of the study or who had discontinued due to lack of efficacy after at least 21 days of treatment. exclusion criteria: * not eligible to enter the open-label phase if believed to be at significant risk for suicidal or violent behavior during the open-label extension trial * were pregnant * or had received an injection of a depot antipsychotic since entry into the preceding double-blind phase

Keywords: paliperidone schizophrenia
a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of amg 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Summary: a randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps


Eligibility criteria:
healthy volunteers: inclusion criteria: * healthy males and females witha bmi between 18.0 and 32.0 kg/m2, inclusive exclusion criteria: * subject with evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with study evaluation, procedures, or completion. subjects with chronic rhinosinusitis with nasal polyps (crswnp): inclusion criteria: * diagnosis of crswnp (inflammation of the nose and paranasal sinuses characterized in adults by 2 or more symptoms, 1 of which should be either nasal blockage or nasal discharge and/or facial pain and/or reduced smell for greater than 12 weeks) * bilateral nasal polyps of grade 3 or 4 exclusion criteria: * forced expiratory volume (fev1) \</= 70% * asthma exacerbation requiring systemic corticosteroid treatment or hospitalization for \> 24h for treatment of asthma, within 3 months prior to screening or are on a dose of greater than 1000 μg fluticasone.
cordotomy in reducing pain in patients with advanced cancer

Conditions: Advanced Malignant Neoplasm

Summary: this trial studies how well cordotomy works in reducing pain in patients with cancer that has spread to other places in the body (advanced). cordotomy is performed on the spinal cord with a needle and guided by computed tomography scans and is designed to help reduce pain. this study is being done to learn if a cordotomy reduces pain in patients with unmanageable cancer pain.

primary objectives: i. assess the efficacy of cordotomy for patients with unilateral advanced cancer pain. secondary objectives: i. define the patient experience of cordotomy for cancer pain refractory to palliative care. ii. determine whether magnetic resonance imaging (mri) can be used as a noninvasive biomarker for a successful cordotomy. outline: patients are randomized to 1 of 2 groups. group i: patients undergo a cordotomy over 1-2 hours. group ii: patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours. after completion of study, patients are followed up at 2 weeks and once every month for up to 6 months.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent * has undergone 3 palliative care evaluations * pain intensity \>= 4 on a 0-10 numerical scale * unilateral pain due to cancer below the shoulder level (arm, trunk, hip, leg) exclusion criteria: * uncorrectable coagulopathy * large intracranial mass * inability to complete assessment forms * life expectancy \< 1 month * contraindication to intravenous sedation * morphine allergy